论文部分内容阅读
目的探讨慢性阻塞性肺疾病(COPD)患者肺部鲍氏不动杆菌感染的临床特点和耐药情况。方法对78例COPD患者肺部鲍氏不动杆菌感染的临床表现及药敏情况进行回顾分析。结果药物敏感性测定提示该菌对头孢哌酮/舒巴坦耐药率最低,为14.9%,其次为亚胺培南和美罗培南,分别是24.8%和28.2%;对氨苄西林、头孢他啶、头孢吡肟、哌拉西林、左氧氟沙星、莫西沙星、阿米卡星、氨曲南和替卡西林/克拉维酸有较高耐药率,为48.5%～74.8%。结论COPD患者肺部鲍氏不动杆菌感染与年老体弱,广谱抗菌药物及激素应用、呼吸道侵入性操作及呼吸机使用有关,临床表现无特异性,耐药严重,病死率高,应注意预防。
Objective To investigate the clinical features and drug resistance of Acinetobacter baumannii infection in patients with chronic obstructive pulmonary disease (COPD). Methods The clinical manifestations and drug susceptibility of Acinetobacter baumannii infection in 78 patients with COPD were retrospectively analyzed. Results The drug susceptibility test showed that the resistance rate of cefoperazone / sulbactam was 14.9%, followed by imipenem and meropenem, which were 24.8% and 28.2%, respectively. For ampicillin, ceftazidime, ceftazidime The drug resistance rates of oxime, piperacillin, levofloxacin, moxifloxacin, amikacin, aztreonam and ticarcillin / clavulanic acid were 48.5% -74.8%. Conclusion Pulmonary Acinetobacter baumannii infection in COPD patients is related to frailty, broad-spectrum antimicrobial agents and hormones, invasiveness of respiratory tract and the use of ventilator. The clinical manifestations are nonspecific, with severe resistance and high mortality rate. Pay attention to prevention.